CN Patent

CN107801378A — 用于治疗braf‑v600相关的疾病的plx‑8394或plx‑7904

Assigned to Plexxikon Inc · Expires 2018-03-13 · 8y expired

What this patent protects

本公开提供在含有野生型BRAF的细胞中不激活MAPK通路或不诱导MAPK通路基因的表达的情况下医治患有或处于BRAF V600突变或BRAF融合突变相关的疾病或病况的风险的受试者的方法。

USPTO Abstract

本公开提供在含有野生型BRAF的细胞中不激活MAPK通路或不诱导MAPK通路基因的表达的情况下医治患有或处于BRAF V600突变或BRAF融合突变相关的疾病或病况的风险的受试者的方法。

Drugs covered by this patent

pexidartinib-hydrochloride (PEXIDARTINIB HYDROCHLORIDE)

Patent Metadata

Patent number: CN107801378A
Jurisdiction: CN
Classification: —
Expires: 2018-03-13
Drug substance claim: No
Drug product claim: No
Assignee: Plexxikon Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.